Moderna (NASDAQ:MRNA) announced three abstracts accepted for presentation at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
Presentations include a 5-year KEYNOTE-942 oral update on intismeran plus pembrolizumab in resected melanoma, two poster presentations including mRNA-2808 in multiple myeloma, and a live investor webcast on June 1 at 6:15 PM CDT. Intismeran autogene is jointly developed with Merck (MSD outside US/Canada).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MRNA
-0.66%
3 alerts
-0.66%Session close to close
$20.68BMarket Cap
0.1xRel. Volume
In the Apr 21 session, MRNA declined 0.66%, reflecting a mild negative market reaction.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This announcement highlights upcoming ASCO 2026 presentations for intismeran autogene in melanoma an...
Analysis
This announcement highlights upcoming ASCO 2026 presentations for intismeran autogene in melanoma and mRNA-2808 in relapsed or refractory multiple myeloma, plus an investor event on June 1, 2026. It adds visibility but not new efficacy or safety data. In recent months, Moderna’s shares reacted most strongly to events like the $950 million litigation settlement and positive vaccine data, while one melanoma update on Apr 17, 2026 saw a divergence, emphasizing the importance of detailed readouts.
Key Figures
ASCO meeting dates:May 29 - June 2, 2026Abstract count:3 abstractsOral abstract number:Abstract #9500+4 more
7 metrics
ASCO meeting datesMay 29 - June 2, 20262026 American Society of Clinical Oncology Annual Meeting timing
Abstract count3 abstractsInvestigational mRNA therapeutics accepted for ASCO 2026
Oral abstract numberAbstract #9500KEYNOTE-942 5-year update in resected melanoma
Poster abstract numberAbstract #9564Intismeran autogene as adjuvant therapy in melanoma
Phase 1/2 trialPhase 1/2mRNA-2808 study in relapsed or refractory multiple myeloma
Investor event dateJune 1, 2026Moderna investor event webcast at ASCO
EMA committee’s positive opinion for mCOMBRIAX combination vaccine.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has often been followed by positive moves, especially on legal resolutions and vaccine data, with one notable divergence where strong oncology trial results coincided with a share price decline.
Recent Company History
Over the last few months, Moderna has reported several notable milestones. A Feb 27 positive EU opinion for mCOMBRIAX and the Mar 3 global patent settlement both saw favorable price reactions, as did ESCMID vaccine data on Apr 6. An earnings date announcement on Apr 15 also aligned with a modest gain. By contrast, strong Phase 1/2 melanoma data on Apr 17 was followed by a decline, highlighting some inconsistency in how oncology updates have traded.
Key Terms
neoantigen, adjuvant therapy, phase 1/2, multiple myeloma, +4 more
8 terms
neoantigenmedical
"Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant..."
A neoantigen is a new, abnormal protein piece that appears on a cancer cell because of a mutation and is not found on healthy cells; think of it as a unique fingerprint the immune system can recognize. It matters to investors because medicines that target neoantigens—such as personalized vaccines or immune therapies—can be highly specific, potentially more effective and safer, and therefore can shape clinical success, regulatory value and commercial potential for oncology drugs.
adjuvant therapymedical
"neoantigen-specific T cells as adjuvant therapy in melanoma"
Adjuvant therapy is an extra medical treatment given after the main treatment—often surgery—to reduce the chance that a disease will come back, such as additional drugs, radiation, or immune-based treatments. For investors it matters because successful adjuvant treatments can expand the market for a drug, influence regulatory approval and reimbursement, and change revenue forecasts much like a protective follow-up step that prevents problems from reappearing.
phase 1/2medical
"A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory..."
Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.
multiple myelomamedical
"mRNA-2808 in participants with relapsed or refractory multiple myeloma"
A cancer of the blood that starts in plasma cells, the immune system’s antibody-producing cells in bone marrow. It behaves like a factory where the workers go rogue, crowding out healthy cells and causing bone damage, anemia and infections; treatments and trial results can sharply affect drug sales, regulatory approvals and company valuations, so progress or setbacks are closely watched by investors.
Hematologic malignancies are types of cancers that start in the blood or the organs responsible for blood production, like the bone marrow and lymph nodes. They matter because they can disrupt normal blood functions, leading to issues like weakness, infections, or abnormal growths, and often require specialized treatments.
A plasma cell dyscrasia is a medical condition in which the antibody-making white blood cells grow or behave abnormally, often producing too much of a single, abnormal protein. For investors, these disorders matter because they range from mild, watch-and-wait conditions to serious cancers that drive demand for diagnostics, therapies and ongoing care; changes in prevalence, treatment approvals, or clinical-trial results can directly affect the value and prospects of healthcare companies.
webcasttechnical
"Moderna will host a live webcast on Monday, June 1, from 6:15 - 7:15 PM CDT."
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
A spoken report given to an audience that summarizes facts, results or plans—often delivered at conferences, meetings or investor events. Investors watch oral presentations because they can reveal new data, management plans or interpretations that affect a company’s prospects; like hearing a coach explain a game plan, the tone, detail and emphasis can change expectations and market reactions almost immediately.
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 - June 2 in Chicago, IL.
The presentation details are as follows:
Oral Presentation:
Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study Session Type/Title: Oral Abstract Session - Melanoma/Skin Cancers Data & Time: June 1, 8:00 AM - 11:00 AM CT Presenter: Matteo S. Carlino, MBBS, PhD, FRACP
Poster Presentations:
Abstract #9564: Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma Session Type/Title: Poster Session - Melanoma/Skin Cancers: Poster Board #280 Date & Time: May 31, 9:00 AM - 12:00 PM CDT Presenter: Ryan J. Sullivan, MD
Abstract #TPS7580: A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma Session Type/Title: Poster Session - Hematologic Malignancies - Plasma Cell Dyscrasia: Poster Board #457b Date & Time: June 1, 9:00 AM - 12:00 PM CDT Presenter: Hans C. Lee, MD
Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
Moderna Investor Event
Moderna will host a live webcast on Monday, June 1, from 6:15 - 7:15 PM CDT. The webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
What ASCO presentations will Moderna (MRNA) deliver at the 2026 meeting?
Moderna will present three abstracts: one oral and two posters at ASCO 2026. According to the company, the oral is a 5-year KEYNOTE-942 update on intismeran plus pembrolizumab in resected melanoma, with two poster studies including mRNA-2808 in multiple myeloma.
When is Moderna's (MRNA) ASCO oral presentation on the KEYNOTE-942 5-year update?
The oral presentation is scheduled for June 1, 8:00 AM–11:00 AM CT. According to the company, Matteo S. Carlino will present the 5-year update on intismeran plus pembrolizumab in resected melanoma during the Melanoma/Skin Cancers oral session.
What is intismeran autogene and who is developing it with Moderna (MRNA)?
Intismeran autogene is an individualized neoantigen therapy developed jointly with Merck. According to the company, intismeran is being evaluated as an adjuvant therapy in melanoma and presented alongside pembrolizumab in the KEYNOTE-942 5-year update.
When and where will Moderna (MRNA) host its investor webcast about ASCO presentations?
Moderna will host a live investor webcast on June 1 from 6:15–7:15 PM CDT. According to the company, the webcast will be available under Events and Presentations in the Investors section at investors.modernatx.com, with a replay archived for at least 30 days.
What Moderna (MRNA) poster presentations are scheduled at ASCO 2026 and when?
Two posters are scheduled: intismeran autogene as adjuvant therapy in melanoma on May 31, 9:00 AM–12:00 PM CDT, and mRNA-2808 in relapsed/refractory multiple myeloma on June 1, 9:00 AM–12:00 PM CDT. According to the company, presenters are Ryan J. Sullivan and Hans C. Lee.
